SOLA Biosciences has announced new preclinical proof-of-concept data for SOL-257, an investigational gene therapy designed to address a core biological feature of ALS. The therapy targets misfolded TDP-43, a protein strongly linked to nerve cell damage in many people with the disease, with the goal of slowing or altering disease progression. This approach is significant because it focuses on an underlying cause of ALS rather than treating symptoms alone. The findings reinforce the potential of gene-based therapies to open new, more effective treatment pathways for patients facing this challenging condition.  Read more (via Business Wire)